Mark Missen

Mark Missen currently serves as the Head of Technical Operations at RoslinCT, a position held since June 2020, where responsibilities include overseeing process development, MSAT, clinical and commercial manufacturing of CRISPR-Cas9 and gene-edited products, as well as support services and planning. Prior to this role, Mark held various leadership positions at Lonza from October 1987 to June 2020, including Head of Manufacturing Operations in the UK and Head of Cell Therapy Operations in Singapore. Mark’s educational background includes a Bachelor of Science in Microbiology from King's College London, earned between 1984 and 1987.